<DOC>
	<DOC>NCT01888471</DOC>
	<brief_summary>Feasibility phase for a study to evaluate antibody levels against Group B Streptococcus in mothers and their infants at delivery to establish antibody levels associated with reductions in risk of GBS disease in infants aged less than 90 days.</brief_summary>
	<brief_title>Feasibility Study Identifying Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Young Infants.</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<criteria>(i) Pregnant women attending antenatal clinic in one of the participating antenatalclinics and/or delivering at one the participating delivery center. (ii) Subjects aged â‰¥18 years. (iii) Able to understand and comply with planned study procedures. (iv) Provides written informed consent. (i) Refuses to consent to study participation.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>serotype specific</keyword>
	<keyword>anti-capsular antibodies</keyword>
	<keyword>Group B Streptococcus</keyword>
	<keyword>Feasibility</keyword>
</DOC>